Audience Discussion: Looking Beyond Intrathecal Administration: Are We Able to Modify Oligonucleotide Chemistry for Intravenous Delivery Across the Blood Brain Barrier?

Time: 1:30 pm
day: Day One

Details:

Achieving intravenous delivery of oligonucleotide therapeutics across the blood brain barrier has long been an attractive prospect for biopharma however despite years of trying to effectively deliver beyond the BBB, a plethora of barriers still remain.

Join this interactive audience discussion to deep dive into the success, failures and challenges of delivering oligonucleotide therapeutics across the blood brain barrier and leave with the knowledge you need to strategically inform and optimize your
intravenous delivery approach.